Alzamend Neuro Meets Nasdaq Equity Listing Requirements

Alzamend Neuro, Inc. has received notification from Nasdaq confirming it has regained compliance with Listing Rule 5550(b)(1), the Equity Rule. The company evidenced stockholders' equity of $5,802,680 in its Quarterly Report on Form 10-Q for the quarter ended July 31, 2026. This resolution ensures the company's continued listing on the Nasdaq exchange.